공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

재생불량성 빈혈 : 파이프라인 리뷰

Aplastic Anemia (Hematology) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 245971
페이지 정보 영문 138 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


재생불량성 빈혈 : 파이프라인 리뷰 Aplastic Anemia (Hematology) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 138 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

재생불량성 빈혈은 말초성 범혈구 감소증 및 골수형성 부전 등의 특징을 가지는 골수 손상증입니다. 증상은 피로, 창백한 피부, 급속 혹은 불규칙한 심박수, 운동에 의한 헐떡임, 코피, 잇몸 출혈, 길어지는 베인 상처에 의한 출혈, 피부 발진, 현기증, 두통 등입니다. 위험인자는 유독 화학물질 노출, 암의 고선량 방사선 치료 또는 화학요법, 특정 혈액질환, 자가면역질환, 심각한 감염증 등입니다. 치료에는 면역억제제와 줄기세포 이식 등이 있습니다.

세계 각국에서의 재생불량성 빈혈(Aplastic Anemia) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요(제품 개요, 작용기전, 연구개발(R&D) 진전 상황), 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 분석 범위

재생불량성 빈혈 개요

치료제 개발

  • 재생불량성 빈혈용 파이프라인 제품 : 개요
  • 기업별 파이프라인
  • 기업에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

재생불량성 빈혈 치료제 개발 참여 기업

  • 3SBio Inc
  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • Novartis AG
  • Pluristem Therapeutics Inc
  • Regen BioPharma Inc

약제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

재생불량성 빈혈 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Aplastic Anemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Aplastic Anemia - Pipeline by Acceleron Pharma Inc, 2021
  • Aplastic Anemia - Pipeline by Amgen Inc, 2021
  • Aplastic Anemia - Pipeline by ASC Therapeutics Inc, 2021
  • Aplastic Anemia - Pipeline by Bellicum Pharmaceuticals Inc, 2021
  • Aplastic Anemia - Pipeline by BioLineRx Ltd, 2021
  • Aplastic Anemia - Pipeline by Cell Source Inc, 2021
  • Aplastic Anemia - Pipeline by Cellenkos Inc, 2021
  • Aplastic Anemia - Pipeline by Elixirgen Therapeutics Inc, 2021
  • Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Aplastic Anemia - Pipeline by Gamida Cell Ltd, 2021
  • Aplastic Anemia - Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2021
  • Aplastic Anemia - Pipeline by HemoGenyx Pharmaceuticals Plc, 2021
  • Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Aplastic Anemia - Pipeline by Novartis AG, 2021
  • Aplastic Anemia - Pipeline by Ono Pharmaceutical Co Ltd, 2021
  • Aplastic Anemia - Pipeline by Pfizer Inc, 2021
  • Aplastic Anemia - Pipeline by Regen BioPharma Inc, 2021
  • Aplastic Anemia - Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Aplastic Anemia - Dormant Projects, 2021
  • Aplastic Anemia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Aplastic Anemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Aplastic Anemia - Overview
  • Aplastic Anemia - Therapeutics Development
  • Aplastic Anemia - Therapeutics Assessment
  • Aplastic Anemia - Companies Involved in Therapeutics Development
  • Aplastic Anemia - Drug Profiles
  • Aplastic Anemia - Dormant Projects
  • Aplastic Anemia - Discontinued Products
  • Aplastic Anemia - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q